Skip to main content
Erschienen in: Clinical and Translational Oncology 10/2012

01.10.2012 | Research Article

Defects in mTR stability and telomerase activity produced by the Dkc1 A353V mutation in dyskeratosis congenita are rescued by a peptide from the dyskerin TruB domain

verfasst von: Rosario Machado-Pinilla, Jaime Carrillo, Cristina Manguan-Garcia, Leandro Sastre, Alexander Mentzer, B.-W. Gu, Philip J. Mason, Rosario Perona

Erschienen in: Clinical and Translational Oncology | Ausgabe 10/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

The predominant X-linked form of dyskeratosis congenita results from mutations in dyskerin, a protein required for ribosomal RNA modification that is also a component of the telomerase complex. We have previously found that expression of an internal fragment of dyskerin (GSE24.2) rescues telomerase activity in X-linked dyskeratosis congenita (X-DC) patient cells.

Materials and Methods

Here, we have generated F9 mouse cell lines expressing the most frequent mutation found in X-DC patients, A353V and study the effect of expressing the GSE24.2 cDNA or GSE24.2 peptide on telomerase activity by TRAP assay, and mTERT and mTR expression by Q-PCR. Point mutation in GSE24.2 residues were generated by site-directed mutagenesis.

Results

Expression of GSE24.2 increases mTR and to a lesser extent mTERT RNA levels, and leads to recovery of telomerase activity. Point mutations in GSE24.2 residues known to be highly conserved and crucial for the pseudouridine-synthase activity of dyskerin abolished the effect of the peptide. Recovery of telomerase activity and increase in mTERT levels were found when the GSE24.2 peptide purified from bacteria was introduced into the cells. Moreover, mTR stability was also rescued by transfection of the peptide GSE24.2.

Discussion

These data indicate that supplying GSE24.2, either from a cDNA vector, or as a peptide, can reduces the pathogenic effects of Dkc1 mutations and could form the basis of a novel therapeutic approach.
Literatur
1.
Zurück zum Zitat Palm W, de Lange T (2008) How shelterin protects mammalian telomeres. Annu Rev Genet 42:301–334PubMedCrossRef Palm W, de Lange T (2008) How shelterin protects mammalian telomeres. Annu Rev Genet 42:301–334PubMedCrossRef
2.
Zurück zum Zitat Osterhage JL, Friedman KL (2009) Chromosome end maintenance by telomerase. J Biol Chem 284:16061–16065PubMedCrossRef Osterhage JL, Friedman KL (2009) Chromosome end maintenance by telomerase. J Biol Chem 284:16061–16065PubMedCrossRef
3.
Zurück zum Zitat Cohen SB, Graham ME, Lovrecz GO et al (2007) Protein composition of catalytically active human telomerase from immortal cells. Science 315:1850–1853PubMedCrossRef Cohen SB, Graham ME, Lovrecz GO et al (2007) Protein composition of catalytically active human telomerase from immortal cells. Science 315:1850–1853PubMedCrossRef
4.
Zurück zum Zitat Meier UT, Blobel G (1994) NAP57, a mammalian nucleolar protein with a putative homolog in yeast and bacteria. J Cell Biol 127:1505–1514PubMedCrossRef Meier UT, Blobel G (1994) NAP57, a mammalian nucleolar protein with a putative homolog in yeast and bacteria. J Cell Biol 127:1505–1514PubMedCrossRef
5.
Zurück zum Zitat Decatur WA, Fournier MJ (2002) rRNA modifications and ribosome function. Trends Biochem Sci 27:344–351PubMedCrossRef Decatur WA, Fournier MJ (2002) rRNA modifications and ribosome function. Trends Biochem Sci 27:344–351PubMedCrossRef
6.
Zurück zum Zitat Ni J, Tien AL, Fournier MJ (1997) Small nucleolar RNAs direct site-specific synthesis of pseudouridine in ribosomal RNA. Cell 89:565–573PubMedCrossRef Ni J, Tien AL, Fournier MJ (1997) Small nucleolar RNAs direct site-specific synthesis of pseudouridine in ribosomal RNA. Cell 89:565–573PubMedCrossRef
7.
Zurück zum Zitat Yang Y, Isaac C, Wang C et al (2000) Conserved composition of mammalian box H/ACA and box C/D small nucleolar ribonucleoprotein particles and their interaction with the common factor Nopp 140. Mol Biol Cell 11:567–577PubMed Yang Y, Isaac C, Wang C et al (2000) Conserved composition of mammalian box H/ACA and box C/D small nucleolar ribonucleoprotein particles and their interaction with the common factor Nopp 140. Mol Biol Cell 11:567–577PubMed
8.
Zurück zum Zitat Heiss NS, Knight SW, Vulliamy TJ et al (1998) X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nat Genet 19:32–38PubMedCrossRef Heiss NS, Knight SW, Vulliamy TJ et al (1998) X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nat Genet 19:32–38PubMedCrossRef
9.
Zurück zum Zitat Kirwan M, Dokal I (2008) Dyskeratosis congenita: a genetic disorder of many faces. Clin Genet 73:103–112PubMedCrossRef Kirwan M, Dokal I (2008) Dyskeratosis congenita: a genetic disorder of many faces. Clin Genet 73:103–112PubMedCrossRef
10.
Zurück zum Zitat Machado-Pinilla R, Sanchez-Perez I, Murguia JR, Sastre L, Perona R (2008) A dyskerin motif reactivates telomerase activity in X-linked dyskeratosis congenita and in telomerase-deficient human cells. Blood 111:2606–2614PubMedCrossRef Machado-Pinilla R, Sanchez-Perez I, Murguia JR, Sastre L, Perona R (2008) A dyskerin motif reactivates telomerase activity in X-linked dyskeratosis congenita and in telomerase-deficient human cells. Blood 111:2606–2614PubMedCrossRef
11.
Zurück zum Zitat Knight SW, Heiss NS, Vulliamy TJ et al (1999) X-linked dyskeratosis congenita is predominantly caused by missense mutations in the DKC1 gene. Am J Hum Genet 65:50–58PubMedCrossRef Knight SW, Heiss NS, Vulliamy TJ et al (1999) X-linked dyskeratosis congenita is predominantly caused by missense mutations in the DKC1 gene. Am J Hum Genet 65:50–58PubMedCrossRef
12.
Zurück zum Zitat Vulliamy TJ, Marrone A, Knight SW et al (2006) Mutations in dyskeratosis congenita: their impact on telomere length and the diversity of clinical presentation. Blood 107:2680–2685PubMedCrossRef Vulliamy TJ, Marrone A, Knight SW et al (2006) Mutations in dyskeratosis congenita: their impact on telomere length and the diversity of clinical presentation. Blood 107:2680–2685PubMedCrossRef
13.
Zurück zum Zitat Mochizuki Y, He J, Kulkarni S, Bessler M, Mason PJ (2004) Mouse dyskerin mutations affect accumulation of telomerase RNA and small nucleolar RNA, telomerase activity, and ribosomal RNA processing. Proc Natl Acad Sci USA 101:10756–10761PubMedCrossRef Mochizuki Y, He J, Kulkarni S, Bessler M, Mason PJ (2004) Mouse dyskerin mutations affect accumulation of telomerase RNA and small nucleolar RNA, telomerase activity, and ribosomal RNA processing. Proc Natl Acad Sci USA 101:10756–10761PubMedCrossRef
14.
Zurück zum Zitat Oh S, Song YH, Kim UJ, Yim J, Kim TK (1999) In vivo and in vitro analyses of Myc for differential promoter activities of the human telomerase (hTERT) gene in normal and tumor cells. Biochem Biophys Res Commun 263:361–365PubMedCrossRef Oh S, Song YH, Kim UJ, Yim J, Kim TK (1999) In vivo and in vitro analyses of Myc for differential promoter activities of the human telomerase (hTERT) gene in normal and tumor cells. Biochem Biophys Res Commun 263:361–365PubMedCrossRef
15.
Zurück zum Zitat Zhao JQ, Hoare SF, McFarlane R et al (1998) Cloning and characterization of human and mouse telomerase RNA gene promoter sequences. Oncogene 16:1345–1350PubMedCrossRef Zhao JQ, Hoare SF, McFarlane R et al (1998) Cloning and characterization of human and mouse telomerase RNA gene promoter sequences. Oncogene 16:1345–1350PubMedCrossRef
16.
Zurück zum Zitat Kalinin A, Thoma NH, Iakovenko A et al (2001) Expression of mammalian geranylgeranyltransferase type-II in Escherichia coli and its application for in vitro prenylation of Rab proteins. Protein Expr Purif 22:84–91PubMedCrossRef Kalinin A, Thoma NH, Iakovenko A et al (2001) Expression of mammalian geranylgeranyltransferase type-II in Escherichia coli and its application for in vitro prenylation of Rab proteins. Protein Expr Purif 22:84–91PubMedCrossRef
17.
Zurück zum Zitat Wright WE, Shay JW, Piatyszek MA (1995) Modifications of a telomeric repeat amplification protocol (TRAP) result in increased reliability, linearity and sensitivity. Nucleic Acids Res 23:3794–3795PubMedCrossRef Wright WE, Shay JW, Piatyszek MA (1995) Modifications of a telomeric repeat amplification protocol (TRAP) result in increased reliability, linearity and sensitivity. Nucleic Acids Res 23:3794–3795PubMedCrossRef
18.
Zurück zum Zitat Sanchez-Perez I, Murguia JR, Perona R (1998) Cisplatin induces a persistent activation of JNK that is related to cell death. Oncogene 16:533–540PubMedCrossRef Sanchez-Perez I, Murguia JR, Perona R (1998) Cisplatin induces a persistent activation of JNK that is related to cell death. Oncogene 16:533–540PubMedCrossRef
19.
Zurück zum Zitat Mitchell JR, Wood E, Collins K (1999) A telomerase component is defective in the human disease dyskeratosis congenita. Nature 402:551–555PubMedCrossRef Mitchell JR, Wood E, Collins K (1999) A telomerase component is defective in the human disease dyskeratosis congenita. Nature 402:551–555PubMedCrossRef
20.
Zurück zum Zitat Ramamurthy V, Swann SL, Paulson JL, Spedaliere CJ, Mueller EG (1999) Critical aspartic acid residues in pseudouridine synthases. J Biol Chem 274:22225–22230PubMedCrossRef Ramamurthy V, Swann SL, Paulson JL, Spedaliere CJ, Mueller EG (1999) Critical aspartic acid residues in pseudouridine synthases. J Biol Chem 274:22225–22230PubMedCrossRef
21.
Zurück zum Zitat Spedaliere CJ, Hamilton CS, Mueller EG (2000) Functional importance of motif I of pseudouridine synthases: mutagenesis of aligned lysine and proline residues. Biochemistry 39:9459–9465PubMedCrossRef Spedaliere CJ, Hamilton CS, Mueller EG (2000) Functional importance of motif I of pseudouridine synthases: mutagenesis of aligned lysine and proline residues. Biochemistry 39:9459–9465PubMedCrossRef
22.
Zurück zum Zitat Zucchini C, Strippoli P, Biolchi A et al (2003) The human TruB family of pseudouridine synthase genes, including the Dyskeratosis Congenita 1 gene and the novel member TRUB1. Int J Mol Med 11:697–704PubMed Zucchini C, Strippoli P, Biolchi A et al (2003) The human TruB family of pseudouridine synthase genes, including the Dyskeratosis Congenita 1 gene and the novel member TRUB1. Int J Mol Med 11:697–704PubMed
23.
Zurück zum Zitat Wong JM, Collins K (2006) Telomerase RNA level limits telomere maintenance in X-linked dyskeratosis congenita. Genes Dev 20:2848–2858PubMedCrossRef Wong JM, Collins K (2006) Telomerase RNA level limits telomere maintenance in X-linked dyskeratosis congenita. Genes Dev 20:2848–2858PubMedCrossRef
24.
25.
Zurück zum Zitat de la Fuente J, Dokal I (2007) Dyskeratosis congenita: advances in the understanding of the telomerase defect and the role of stem cell transplantation. Pediatr Transplant 11:584–594PubMedCrossRef de la Fuente J, Dokal I (2007) Dyskeratosis congenita: advances in the understanding of the telomerase defect and the role of stem cell transplantation. Pediatr Transplant 11:584–594PubMedCrossRef
26.
27.
Zurück zum Zitat Zeng XL, Thumati NR, Fleisig HB et al (2011) The accumulation and not the specific activity of telomerase ribonucleoprotein determines telomere maintenance deficiency in X-linked dyskeratosis congenita. Hum Mol Genet (epub ahead of print Nov 16) Zeng XL, Thumati NR, Fleisig HB et al (2011) The accumulation and not the specific activity of telomerase ribonucleoprotein determines telomere maintenance deficiency in X-linked dyskeratosis congenita. Hum Mol Genet (epub ahead of print Nov 16)
Metadaten
Titel
Defects in mTR stability and telomerase activity produced by the Dkc1 A353V mutation in dyskeratosis congenita are rescued by a peptide from the dyskerin TruB domain
verfasst von
Rosario Machado-Pinilla
Jaime Carrillo
Cristina Manguan-Garcia
Leandro Sastre
Alexander Mentzer
B.-W. Gu
Philip J. Mason
Rosario Perona
Publikationsdatum
01.10.2012
Verlag
Springer Milan
Erschienen in
Clinical and Translational Oncology / Ausgabe 10/2012
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-012-0865-4

Weitere Artikel der Ausgabe 10/2012

Clinical and Translational Oncology 10/2012 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.